Colorectal Cancer Therapeutics in Asia-Pacific Markets to 2023 - Launch of Premium Targeted Therapies and Increasing Prevalence to Drive the Market

  • ID: 4342569
  • Report
  • Region: Asia Pacific
  • 143 Pages
  • GBI Research
1 of 5
CRC Asia-Pacific Market will be Valued at $7.9 Billion in 2023, Growing from $4.7 Billion in 2016 at a CAGR of 7.9%

FEATURED COMPANIES

  • AB Science
  • Array BioPharma
  • Eli Lilly
  • Jiangsu Chia-Tai Tianqing
  • Onyx
  • Roche
  • MORE

Summary

Colorectal cancer (CRC) originates in either the colon or the rectum. It is one of the most common types of cancers, and is the third most common cancer among men and the second most common in women (ACS, 2017a; Ferlay et al., 2016). CRC is a high-mortality cancer, with mortality rates just behind those of lung, liver, and stomach cancer. It’s global age-standardized mortality rates are 20.6 and 14.3 deaths per 100,000 population for men and women, respectively (Ferlay et al., 2016). Most cases of CRC present as adenocarcinomas, but other types of CRC include gastrointestinal carcinoid tumors, gastrointestinal stromal tumors, primary colorectal lymphoma, leiomyosarcoma, melanoma and squamous cell carcinoma (Kim et al., 2016).

China has the most newly diagnosed CRC cases in Asia-Pacific (APAC). In 2011, there were 310,200 incident cases in the country and this rose to 376,300 in 2015. CRC is the most common malignancy among Chinese males, with an estimated incidence of 215,700 men and 160,600 women in 2015. Mortality in 2011 stood at 149,700, and in 2015 rose to 191,000 (Chen et al., 2016).

In Japan, the incidence and mortality of CRC have substantially increased. In 2012, the incidence of colon and rectum cancer in Japan was 87,800 and 46,800 cases respectively, and mortality was 32,200 and 15,100 cases (NCC, 2016a). CRC is a major cause of death in Japan, where it accounts for the largest number of deaths from malignant neoplasms among women, and the third largest among men (Watanabe et al., 2015). In 2016, there were an estimated 147,200 new CRC cases and 51,600 deaths in the country (NCC, 2016b).

In Australia, the five-year survival rate increased from 50% between 1984 and 1988 to 69% between 2009 and 2013. Improvement in survival from CRC may be due to earlier diagnosis and the availability of better treatment options (AGCA, 2017). The incidence of CRC is still several folds lower in India than in most developing and developed countries (Mallath, 2014). However, the country has witnessed a steady increase in numbers in line with its increasing urbanization.

The report “Colorectal Cancer Therapeutics in Asia-Pacific Markets to 2023 - Launch of Premium Targeted Therapies and Increasing Prevalence to Drive the Market” analyzes the CRC pipeline and stratify pipeline therapies by stage of development, molecule type and molecular target. Furthermore, this report helps to understand the current clinical and commercial landscape by considering disease pathogenesis, diagnosis, prognosis, and the treatment options available at each stage of diagnosis, including a clinical comparison of marketed therapies.

Companies mentioned in this report: Merck & Co., Roche, Sumitomo Dainippon Pharma, Array BioPharma, AB Science, Hutchison MediPharma, Jiangsu Chia-Tai Tianqing, Suzhou Zelgen Biopharmaceuticals

Scope

The CRC Asia-Pacific market will be valued at $7.9 billion in 2023, growing from $4.7 billion in 2016 at a CAGR of 7.9%.

  • How will immune checkpoint inhibitors such as Keytruda and Tecentriq contribute to growth?
  • What effect will patent expirations of currently branded therapies have on market value?

The CRC pipeline is large and diverse, with an strong presence of mAbs and targeted therapies.

  • What are the common targets and mechanisms of action of pipeline therapies?
  • Will the pipeline address unmet needs such as the lack of targeted therapies available for BRAF-mutant CRC patients?
  • What implications will the increased focus on targeted therapies have on the future of CRC treatment?

Numerous late-stage pipeline therapies with a strong clinical record have the potential to enter the market over the forecast period.

  • How have the late-stage therapies performed in clinical trials?
  • How would the approval of encorafenib plus binimetinib to treat BRAF-mutant patients affect the competitive landscape, with no targeted therapy currently available to address this patient subset?

The market forecasts indicate that Japan will contribute the most to the Asia-Pacific market value due to the emergence of novel therapies.

  • How will the annual cost of therapy and market size vary between the five assessed Asia-Pacific markets?
  • How could changes in risk factors such as population age, obesity and lifestyle influence the market?

Licensing deals are the most common form of strategic alliance in CRC, with total deal values ranging from under $10m to over $3 billion.

  • How do deal frequency and value compare between target families and molecule types?
  • What were the terms and conditions of key licensing deals?

Reasons to buy

  • Understand the current clinical and commercial landscape by considering disease pathogenesis, diagnosis, prognosis, and the treatment options available at each stage of diagnosis, including a clinical comparison of marketed therapies.
  • Visualize the composition of the CRC market in terms of the dominant therapies for each patient subset, along with their clinical and commercial standing. Unmet needs are highlighted to allow a competitive understanding of gaps in the market.
  • Analyze the CRC pipeline and stratify pipeline therapies by stage of development, molecule type and molecular target.
  • Understand the potential of late-stage therapies with extensive profiles of products that could enter the market over the forecast period, highlighting clinical performance, potential commercial positioning, and how they will compete with other therapies.
  • Predict CRC market growth in the five assessed Asia-Pacific markets, with epidemiological and annual cost of therapy forecasts across India, China, Australia, South Korea and Japan, as well as the individual contributions of promising late-stage molecules to market growth.
  • Identify commercial opportunities in the CRC deals landscape by analyzing trends in licensing and co-development deals.
READ MORE
Note: Product cover images may vary from those shown
2 of 5

FEATURED COMPANIES

  • AB Science
  • Array BioPharma
  • Eli Lilly
  • Jiangsu Chia-Tai Tianqing
  • Onyx
  • Roche
  • MORE

1 Table of Contents

2 Introduction
2.1 Disease Introduction
2.2 Epidemiology
2.3 Symptoms
2.4 Etiology and Pathophysiology
2.4.1 Etiology
2.4.2 Pathophysiology
2.4.3 Biomarkers/Targets of Interest
2.5 Diagnosis
2.5.1 Digital Rectal Examination
2.5.2 Fecal Occult Blood Test
2.5.3 Flexible Sigmoidoscopy
2.5.4 Colonoscopy
2.5.5 Virtual Colonoscopy
2.5.6 Double Contrast Barium Enema
2.6 Disease Stages
2.7 Prognosis
2.8 Treatment Guidelines and Options
2.8.1 Surgery and Radiation Therapy
2.8.2 Chemotherapy
2.8.3 Targeted Therapies
2.8.4 Resistance to Pharmacological Therapies
2.8.5 Treatment Algorithm

3 Marketed Products
3.1 Overview
3.2 Chemotherapies
3.2.1 Lonsurf (Trifluridine plus Tipiracil) - Taiho Pharma
3.2.2 TS-1 (Tegafur plus Gimeracil plus Oteracil) - Taiho Pharma
3.2.3 UFT (tegafur plus uracil) - Merck KGaA
3.3 Epidermal Growth Factor Receptor Targeted Therapies
3.3.1 Erbitux (cetuximab) - Eli Lilly/Merck KGaA
3.3.2 Vectibix (panitumumab) - Amgen/Takeda
3.4 Anti-angiogenesis Therapies
3.4.1 Avastin (bevacizumab) - Roche
3.4.2 Cyramza (ramucirumab) - Eli Lilly
3.4.3 Zaltrap (Ziv-Aflibercept) - Sanofi/Regeneron
3.5 Kinase Inhibitors
3.5.1 Stivarga (regorafenib) - Bayer/Onyx
3.6 Comparative Efficacy and Safety of Marketed Products

4 Pipeline Analysis
4.1 Overview
4.2 Pipeline by Stage of Development, Molecule Type, Route of Administration and Program Type
4.3 Pipeline by Molecular Target
4.4 Promising Pipeline Candidates
4.4.1 Keytruda (pembrolizumab) - Merck & Co.
4.4.2 Tecentriq plus Cotellic (Atezolizumab plus cobimetinib) - Roche
4.4.3 Napabucasin (BBI-608) - Sumitomo Dainippon Pharma
4.4.4 Encorafenib plus binimetinib (LGX-818/MEK-162) - Array BioPharma
4.4.5 Masitinib - AB Science
4.4.6 Fruquintinib (HMPL-013) - Hutchison MediPharma
4.4.7 Famitinib (SHR-1020) - Jiangsu Hengrui Medicine
4.4.8 Anlotinib (AL-3818) - Jiangsu Chia-Tai Tianqing
4.4.9 Donafenib (CM-4307) - Suzhou Zelgen Biopharmaceuticals
4.5 Comparative Efficacy and Safety of Pipeline Products
4.6 Product Competitiveness Framework

5 Clinical Trial Analysis
5.1 Failure Rate
5.1.1 Overall Failure Rate
5.1.2 Failure Rate by Phase and Molecule Type
5.1.3 Failure Rate by Phase and Molecular Target
5.2 Clinical Trial Size
5.2.1 Patient Enrollment per Product by Molecule Type and Stage of Development
5.2.2 Patient Enrollment per Product by Molecular Target and Stage of Development
5.2.3 Patient Enrollment per Trial by Molecule Type and Stage of Development
5.2.4 Patient Enrollment per Trial by Molecular Target and Stage of Development
5.3 Clinical Trial Duration
5.3.1 Trial Duration by Molecule Type and Stage of Development
5.3.2 Trial Duration by Molecular Target and Stage of Development
5.4 Summary of Clinical Trial Metrics

6 Multi-scenario Forecast
6.1 Overview
6.2 Asia-Pacific Market
6.3 India
6.3.1 Treatment Usage Patterns
6.3.2 Annual Cost of Therapy
6.3.3 Market Size
6.4 China
6.4.1 Treatment Usage Patterns
6.4.2 Annual Cost of Therapy
6.4.3 Market Size
6.5 Australia
6.5.1 Treatment Usage Patterns
6.5.2 Annual Cost of Therapy
6.5.3 Market Size
6.6 South Korea
6.6.1 Treatment Usage Patterns
6.6.2 Annual Cost of Therapy
6.6.3 Market Size
6.7 Japan
6.7.1 Treatment Usage Patterns
6.7.2 Annual Cost of Therapy
6.7.3 Market Size

7 Drivers and Barriers
7.1 Drivers
7.1.1 Increasing Elderly Population and Incidence of CRC
7.1.2 Increasing Screening Programs and Approval of New Screening Tests for CRC to Drive Early Diagnosis Rate
7.1.3 Increase in Mutation Testing to Drive Market Growth
7.1.4 Availability of Novel First-, Second- and third-Line Therapy Options in Pipeline
7.1.5 Diversified Healthcare Reform to Boost Market Growth
7.1.6 Diversified Health Insurance System to Help Nurture Growth
7.2 Barriers
7.2.1 Patent Expiration of Branded Therapies to Affect CRC Market Growth
7.2.2 High Prices of Therapeutics to Slow Down Market Growth
7.2.3 Limited Incorporation of Immunotherapies in the CRC Treatment Algorithm
7.2.4 Lack of Development of Neoadjuvant and Adjuvant Pipeline Products
7.2.5 Lack of Reimbursement and Penetration of Generic Drugs to Hinder Market Growth in China and India
7.2.6 Drug Pricing Reforms

8 Deals and Strategic Consolidations
8.1 Licensing Deals
8.1.1 Deals by Region and Value
8.1.2 Number of Disclosed and Undisclosed Deals by Year, Aggregate Deal Value
8.1.3 Deal Value by Stage of Development, Molecule Type, and Molecular Target
8.1.4 Key Licensing Deals
8.2 Co-development Deals
8.2.1 Deals by Region and Value
8.2.2 Number of Disclosed and Undisclosed Deals by Year, Aggregate Deal Value
8.2.3 Deal Value by Stage of Development, Molecule Type, and Molecular Target
8.2.4 Key Co-development Deals

9 Appendix
9.1 All Pipeline Drugs by Stage of Development
9.1.1 Discovery
9.1.2 Preclinical
9.1.3 Investigational New Drug/Clinical Trial Authorization-Filed
9.1.4 Phase I
9.1.5 Phase II
9.1.6 Phase III
9.1.7 Pre-registration
9.2 Summary of Multi-scenario Market Forecasts to 2023
9.2.1 Asia-Pacific
9.2.2 India
9.2.3 China
9.2.4 Australia
9.2.5 South Korea
9.2.6 Japan
9.3 Bibliography
9.4 Abbreviations
9.5 Research Methodology
9.5.1 Secondary Research
9.5.2 Marketed Product Profiles
9.5.3 Late-Stage Pipeline Candidates
9.5.4 Comparative Efficacy and Safety Heat Map for Marketed and Pipeline Products
9.5.5 Product Competitiveness Framework
9.5.6 Pipeline Analysis
9.5.7 Forecasting Model
9.5.8 Deals Data Analysis

List of Tables
Table 1: CRC Therapeutics Market, Symptoms of CRC
Table 2: CRC Therapeutics Market, Stage Definitions for CRC
Table 3: CRC Therapeutics Market, Prognosis for CRC
Table 4 CRC Therapeutics, Surgical Options for CRC
Table 5: CRC Therapeutics Market, Global, Licensing Deals Valued $10m and Above, 2006-2017
Table 6: CRC Therapeutics Market, Global, Co-development Deals Value, 2006-2016
Table 7: CRC Therapeutics Market, Global, All Pipeline Products, Discovery, 2017
Table 8: CRC Therapeutics Market, Global, All Pipeline Products, Preclinical, 2017
Table 9: CRC Therapeutics Market, Global, All Pipeline Products, IND/CTA-Filed, 2017
Table 10: CRC Therapeutics Market, Global, All Pipeline Products, Phase I, 2017
Table 11: CRC Therapeutics Market, Global, All Pipeline Products, Phase II, 2017
Table 12: CRC Therapeutics Market, Global, All Pipeline Products, Phase III, 2017
Table 13: CRC Therapeutics Market, Global, All Pipeline Products, Pre-registration, 2017
Table 14: CRC Therapeutics Market, APAC, Market Forecast, 2016-2023
Table 15: CRC Therapeutics Market, India, Market Forecast, 2016-2023
Table 16: CRC Therapeutics Market, China, Market Forecast, 2016-2023
Table 17: CRC Therapeutics Market, Australia, Market Forecast, 2016-2023
Table 18: CRC Therapeutics Market, South Korea, Market Forecast, 2016-2023
Table 19: CRC Therapeutics Market, Japan, Market Forecast, 2016-2023

List of Figures
Figure 1: CRC Therapeutics Market, Australia, Age-Specific Incidence and Mortality Rate (per 100,000) in 2013
Figure 2: CRC Therapeutics, Treatment Algorithm for mCRC
Figure 3: CRC Therapeutics Market, Comparative Efficacy and Safety Heatmap for Marketed Products
Figure 4: CRC Therapeutics Market, Global, Pipeline, 2017
Figure 5: CRC Therapeutics Market, Global, Pipeline by Molecular Target, 2017
Figure 6: CRC Therapeutics Market, Pipeline by Molecular Target and Stage of Development, 2017
Figure 7: CRC Therapeutics Market, APAC, Keytruda Forecast ($m), 2021-2023
Figure 8: CRC Therapeutics Market, APAC, Tecentriq plus Cotellic Forecast ($m), 2021-2023
Figure 9: CRC Therapeutics Market, APAC, Napabucasin Forecast ($m), 2021-2023
Figure 10: CRC Therapeutics Market, APAC, Encorafenib plus Binimetinib Forecast ($m), 2021-2023
Figure 11: CRC Therapeutics Market, APAC, Masitinib Forecast ($m), 2019-2023
Figure 12: CRC Therapeutics Market, APAC, Fruquintinib Forecast ($m), 2018-2023
Figure 13: CRC Therapeutics Market, APAC, Famitinib Forecast ($m), 2019-2023
Figure 14: CRC Therapeutics Market, APAC, Anlotinib Forecast ($m), 2020-2023
Figure 15: CRC Therapeutics Market, APAC, Donafenib Forecast ($m), 2021-2023
Figure 16: CRC Therapeutics Market, Comparative Efficacy and Safety Heatmap for Pipeline Products
Figure 17: CRC Therapeutics Market, Competitor Matrix for CRC Marketed and Pipeline First-Line Products, 2017
Figure 18: CRC Therapeutics, Global, Average Clinical Trial Failure Rate (%), 2006-2016
Figure 19: CRC Therapeutics, Global, Clinical Trial Failure Rates by Molecule Type (%), 2006-2016
Figure 20: CRC Therapeutics, Global, Clinical Trial Failure Rates by Molecular Target (%), 2006-2016
Figure 21: CRC Therapeutics, Global, Clinical Trial Size per Product by Molecule Type (participants), 2006-2016
Figure 22: CRC Therapeutics, Global, Clinical Trial Size per Product by Molecular Target (participants), 2006-2016
Figure 23: CRC Therapeutics, Global, Clinical Trial Size per Trial by Molecule Type (participants), 2006-2016
Figure 24: CRC Therapeutics, Global, Clinical Trial Size per Trial by Molecular Target (participants), 2006-2016
Figure 25: CRC Therapeutics, Global, Clinical Trial Duration by Molecule Type (months), 2006-2016
Figure 26: CRC Therapeutics, Global, Clinical Trial Duration by Molecular Target (months), 2006-2016
Figure 27: CRC Therapeutics Market, Global, Comparison of Average Trial Metrics by Phase and Molecule Type
Figure 28: CRC Therapeutics Market, Global, Comparison of Average Trial Metrics by Phase and Molecular Target
Figure 29: CRC Therapeutics Market, APAC, Treatment Patterns (‘000), 2016-2023
Figure 30: CRC Therapeutics Market, APAC, Market Size ($bn), 2016-2023
Figure 31: CRC Therapeutics Market, India, Treatment Patterns (‘000), 2016-2023
Figure 32: CRC Therapeutics Market, India, Annual Cost of Therapy ($), 2016-2023
Figure 33: CRC Therapeutics Market, India, Market Size ($m), 2016-2023
Figure 34: CRC Therapeutics Market, China, Treatment Patterns (‘000), 2016-2023
Figure 35: CRC Therapeutics Market, China, Annual Cost of Therapy ($), 2016-2023
Figure 36: CRC Therapeutics Market, China, Market Size ($bn), 2016-2023
Figure 37: CRC Therapeutics Market, Australia, Treatment Patterns (‘000), 2016-2023
Figure 38: CRC Therapeutics Market, Australia, Annual Cost of Therapy ($), 2016-2023
Figure 39: CRC Therapeutics Market, Australia, Market Size ($m), 2016-2023
Figure 40: CRC Therapeutics Market, South Korea, Treatment Patterns (‘000), 2016-2023
Figure 41: CRC Therapeutics Market, South Korea, Annual Cost of Therapy ($), 2016-2023
Figure 42: CRC Therapeutics Market, South Korea, Market Size ($m), 2016-2023
Figure 43: CRC Therapeutics Market, Japan, Treatment Patterns (‘000), 2016-2023
Figure 44: CRC Therapeutics Market, Japan, Annual Cost of Therapy ($), 2016-2023
Figure 45: CRC Therapeutics Market, Japan, Market Size ($bn), 2016-2023
Figure 46: CRC Therapeutics Market, Global, Licensing Deals by Region and Value, 2006-2017
Figure 47: CRC Therapeutics Market, Global, Number of Disclosed and Undisclosed Licensing Deals by Year, Aggregate Deal Value and Aggregate Upfront Payment Value, 2006-2017
Figure 48: CRC Therapeutics Market, Global, Licensing Deals by Stage of Development, Deal Value and Upfront Payment Value, 2006-2017
Figure 49: CRC Therapeutics Market, Global, Licensing Deals by Molecule Type and Stage of Development, 2006-2017
Figure 50: CRC Therapeutics, Global, Licensing Deals by Molecular Targets and Aggregate Deal Value ($), 2006-2017
Figure 51: CRC Therapeutics Market, Global, Co-development Deals by Region and Deal Value, 2006-2017
Figure 52: CRC Therapeutics Market, Global, Number of Disclosed and Undisclosed Co-development Deals by Year, Aggregate Deal Value and Aggregate Upfront Payment Value, 2006-2017
Figure 53: CRC Therapeutics Market, Global, Co-development Deals by Stage of Development, Deal Value and Upfront Payment Value, 2006-2017
Figure 54: CRC Therapeutics Market, Global, Co-development Deals by Molecule type and Stage of Development, 2006-2016
Figure 55: CRC Therapeutics Market, Global, Co-development Deals by Molecular Target, 2006-2016

Note: Product cover images may vary from those shown
3 of 5

Loading
LOADING...

4 of 5
  • AB Science
  • Amgen
  • Array BioPharma
  • Bayer
  • Eli Lilly
  • Hutchison MediPharma
  • Jiangsu Chia-Tai Tianqing
  • Merck & Co.
  • Onyx
  • Regeneron
  • Roche
  • Sanofi
  • Sumitomo Dainippon Pharma
  • Suzhou Zelgen Biopharmaceuticals
  • Taiho Pharma
  • Takeda
Note: Product cover images may vary from those shown
5 of 5
Note: Product cover images may vary from those shown
Adroll
adroll